Archive:
Staatssekretär Dr. Klaus Theo Schröder im MVF-Titelinterview: ein Jahr Realität in der deutschen Versorgungsforschung
01.04.2009
Die medikamentöse Therapie des Diabetes mellitus Typ 2 erfolgt vor allem mit oralen Antidiabetika, im fortgeschrittenen Stadium auch mit Insulinen. Im letzten Jahr stiegen die Ausgaben für orale Antidiabetika mit knapp zwölf Prozent doppelt so stark wie der gesamte Arzneimittelmarkt und repräsentieren innerhalb der GKV mittlerweile ein Ausgabenniveau von über einer halben Milliarde Euro. Zwischen […]
01.04.2009
Sie ist eine der zentralen Herausforderungen des Gesundheitssystems – die Volkskrankheit Diabetes mellitus Typ 2. Mit einer klar steigenden Tendenz und erheblichem Risikopotenzial für die Versicherten. Doch nicht die Diabetes-Erkrankung an sich schränkt das Leben der Betroffenen ein, erhöht die Sterblichkeit und bedingt einen massiven Ressourceneinsatz des Systems, sondern vielmehr die damit assoziierten Folgeerkrankungen wie […]
01.04.2009
LIVE-SPP Study (Long Acting Insulin Glargine Versus NPH Cost Evaluation in Specialized Practices
01.04.2009
Mit dem Inkrafttreten des ersten hausarztzentrierten Versorgungsvertrags nach dem neuen §73b SGB V am 1. Juli 2008 begann der Aufbau der eHealth-Infrastruktur in Baden-Württemberg. Über 1.200 Hausärzte sind über die hoch sichere Infrastruktur bereits online vernetzt. >> Der hausarztzentrierte Versorgungsvertrag (HZV) zwischen AOK Baden-Württemberg, Hausärztlicher Vertragsgemeinschaft (HÄVG) und MEDI Verbund sichert teilnehmenden Ärzten nicht nur […]
01.04.2009
With the Statutory Health Insurance Competition Strengthening Act (GKV-WSG), the Institute for Quality and Efficiency in Health Care (IQWiG) has been given the additional task of carrying out the economic evaluation of medicines in the form of cost-benefit assessments. In their last article for this magazine (MVF 1/2009: 32-37), the head of IQWiG, Prof. Dr. med. Peter Sawicki and two of his employees briefly presented the methodology newly developed by IQWiG and its motivation. Against the background of many years of research in health economics, the conclusion is disappointing. Neither the internationally applied standards of scientific research were taken into account, nor were the long-standing experiences of other comparable assessment agencies such as the National Institute for Health and Clinical Excellence (NICE) taken into account in the specific design of the cost-benefit assessment. The hope remains that with the presentation and discussion of the recently commissioned pilot studies, the influence of health economics experts will increase again in order to move the German special approach in cost-benefit assessment more towards the standards accepted in health economics.
01.04.2009
In Germany, health economic instruments for drug evaluation were introduced for the first time through the GKV Modernization Act. The basis for this economic evaluation of medicines is the international standards of health economics, which are explicitly required by law. The draft methods presented by IQWiG have so far been inadequate and have been subject to widespread criticism. The efficiency frontier concept proposed by IQWiG is subject to many methodological shortcomings. In addition, the QALY is strictly rejected as a cross-indication benefit measure. The chosen perspective of the insured community and the close integration of the benefit parameters also do not correspond to the international standard. The IQWiG proposal is therefore not suitable for creating the necessary instructions for carrying out cost-benefit assessments of new medical technologies. A look at the international methods that have been established in many other countries for some time shows all the necessary solutions. This solution will also have an impact on the healthcare research landscape.